A skin cancer survivor from Pocklington is preparing to take part in the London Marathon for Yorkshire Cancer Research.
Sharron Anderson, a member of Pocklington Runners, will take part in the 26.2 mile challenge on Sunday, April 23.
It will be the fifth marathon Sharron has completed, with the Edinburgh Marathon, the Chester Marathon and the Yorkshire Marathon already under her belt.
Sharron was diagnosed with malignant melanoma in April 2015. She went to see her GP after noticing a new fast-growing mole on her leg, but was told it was nothing to worry about.
A year later, a raised, red spot appeared in the centre of the mole, which scabbed over. She returned to her doctors, and was quickly referred to York Hospital. A biopsy revealed the growth was cancerous, and she was transferred to St James’s University Hospital in Leeds for treatment.
Sharron underwent surgery to remove the melanoma, which was 4mm deep, and several satellite clusters of cancerous cells around the original mole. Thankfully, a further biopsy and a CT scan revealed that the cancer had not spread any further.
Sharron has now been ‘cancer free’ for 18 months and will undergo regular check-ups for the next three years.
She said: “I’m looking forward to raising money for Yorkshire Cancer Research through my participation in the London Marathon. It’s my way of saying thank you for the fantastic care I have received.
“Before my diagnosis I’d already completed a couple of marathons, some half marathons and a number of 10Ks. Running has helped me massively during my experience with cancer. The social side gives me a great support network and the actual training gives me time to empty my head and put things in perspective.”
Adrienne Hodgson, Regional Fundraiser at Yorkshire Cancer Research, said: “We’re incredibly grateful to Sharron for choosing to raise money for Yorkshire Cancer Research through her participation in the London Marathon. She’s an extremely inspiring lady and we wish her the best of luck for the day.
“The money raised will help more people in Yorkshire survive cancer by raising awareness of cancer and how to prevent it, promoting the national cancer screening programmes and supporting innovative research projects, from diagnosis to end of life care.”
For more information about fundraising for Yorkshire Cancer Research, please visit www.ycr.org.uk/teamyorkshire.
Nikki Brady, Senior PR Officer, Yorkshire Cancer Research. Tel: 01423 877228. Email: email@example.com
Notes to Editors
- Harrogate-based Yorkshire Cancer Research was founded in 1925 and is the largest independent regional cancer charity in England (Registered Charity 516898). We are not part of a national charity.
- We are committed to reducing the devastating impact of cancer on the lives of people living in Yorkshire.
- Our mission is to work in partnership, fund research and support initiatives that will help people in Yorkshire avoid, survive and cope with cancer.
- Current statistics show that 575 people are diagnosed with cancer in Yorkshire every week. Incidence and mortality rates are higher than the England average due to social deprivation, post-industrialisation and lifestyle choices but also availability of healthcare services and difficulties accessing early diagnostics, clinical trials and the latest treatments.
- We aim to:
- Be the leading authority on cancer in Yorkshire, understanding the problems and priorities in the region and sharing knowledge with partners.
- Raise awareness of cancer and how to prevent it by working in local communities, schools and colleges, sports clubs and with other health-related organisations.
- Promote screening programmes and fund research that can improve the diagnosis of cancer so we can detect and treat it at the earliest opportunity.
- Invest in innovative research projects at every stage of a cancer patient's journey.
- Campaign for fair and equal access to the very best healthcare services and a greater share of the money spent nationally on research.
- For further information, please visit www.yorkshirecancerresearch.org.uk or follow us on Facebook or Twitter.